IS5572A - Orkuríkar sýklódextrínfléttur - Google Patents

Orkuríkar sýklódextrínfléttur

Info

Publication number
IS5572A
IS5572A IS5572A IS5572A IS5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A IS 5572 A IS5572 A IS 5572A
Authority
IS
Iceland
Prior art keywords
rich
energy
cyclodextrin complexes
cyclodextrin
complexes
Prior art date
Application number
IS5572A
Other languages
English (en)
Icelandic (is)
Inventor
Loftsson Thorsteinn
βr M βsson M
Stef βnsson Einar
Original Assignee
Cyclops Ehf.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclops Ehf. filed Critical Cyclops Ehf.
Publication of IS5572A publication Critical patent/IS5572A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5572A 1998-02-23 2000-07-25 Orkuríkar sýklódextrínfléttur IS5572A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7554498P 1998-02-23 1998-02-23
PCT/IS1999/000003 WO1999042111A1 (fr) 1998-02-23 1999-02-16 Complexes de cyclodextrine extremement energetiques

Publications (1)

Publication Number Publication Date
IS5572A true IS5572A (is) 2000-08-16

Family

ID=22126450

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5572A IS5572A (is) 1998-02-23 2000-07-25 Orkuríkar sýklódextrínfléttur

Country Status (7)

Country Link
EP (1) EP1067942A1 (fr)
JP (1) JP2003522207A (fr)
AU (1) AU759280C (fr)
CA (1) CA2320772A1 (fr)
IS (1) IS5572A (fr)
NZ (1) NZ505951A (fr)
WO (1) WO1999042111A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7937500A (en) * 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
EP1267941B1 (fr) * 2000-03-28 2005-11-23 Farmarc Nederland B.V. Complexes d'inclusion d'alprazolame et compositions pharmaceutiques les contenant
NZ530227A (en) 2001-06-18 2006-09-29 Noven Pharma Enhanced drug delivery in transdermal systems
WO2003022270A1 (fr) * 2001-09-13 2003-03-20 Noven Pharmaceuticals, Inc. Administration transcutanee d'un ester d'enalapril
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
SI1515729T1 (sl) * 2002-06-13 2008-08-31 Novartis Ag Kvaternizirane amonij ciklodekstrinske spojine
RS20050735A (en) 2003-03-28 2008-06-05 Ares Trading S.A., Cladribine formulations for improved oral and transmucosal delivery
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
RU2390330C2 (ru) 2003-12-31 2010-05-27 Сайдекс, Инк. Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
MXPA06012240A (es) 2004-04-23 2007-01-31 Cydex Inc Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
MX348982B (es) 2005-10-26 2017-07-06 Cydex Pharmaceuticals Inc Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US8455471B2 (en) * 2006-10-20 2013-06-04 Icos Corporation Compositions of CHK1 inhibitors and cyclodextrin
JP2010510311A (ja) * 2006-11-21 2010-04-02 ノバルティス アーゲー ベンゾジアゼピン構造のrsv阻害剤を含む安定な非経腸製剤
EP3766493B1 (fr) 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Méthode de stabilisation du clopidogrel en utilisant de la sulfoalkyl-éther cyclodextrine
EP2106786A1 (fr) 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Préparation pharmaceutique comprenant du cyclodextrine permethylé
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
AU2009335206B2 (en) 2008-12-29 2013-03-14 Unilever Plc Food products enriched with methylxanthines
JP5808739B2 (ja) 2009-05-13 2015-11-10 サイデックス・ファーマシューティカルズ・インコーポレイテッド プラスグレル及びシクロデキストリン誘導体を含む医薬組成物並びにその製造方法及び使用方法
AU2011254726B2 (en) 2010-05-19 2014-03-06 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
EP2678320B1 (fr) 2011-02-23 2018-09-19 Coeruleus Ltd. Complexes de flumazénil, compositions les comprenant et leurs utilisations
DK2814849T3 (da) 2012-02-15 2020-03-09 Cydex Pharmaceuticals Inc Fremgangsmåde til fremstilling af cyclodextrin-derivater
CA2865950C (fr) 2012-02-28 2016-12-20 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylee et procedes pour leur preparation et leur utilisation
NZ707323A (en) 2012-10-22 2018-11-30 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
KR102147084B1 (ko) 2012-11-15 2020-08-24 자피오텍 게엠베하 소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제
EP2931287B1 (fr) 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin contre les cellules de mélanome
WO2016029179A1 (fr) 2014-08-22 2016-02-25 Cydex Pharmaceuticals, Inc. Compositions de cyclodextrine alkylée fractionnées et leurs procédés de préparation et d'utilisation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation

Also Published As

Publication number Publication date
AU2638599A (en) 1999-09-06
JP2003522207A (ja) 2003-07-22
CA2320772A1 (fr) 1999-08-26
AU759280C (en) 2004-01-22
AU759280B2 (en) 2003-04-10
WO1999042111A1 (fr) 1999-08-26
EP1067942A1 (fr) 2001-01-17
NZ505951A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
IS5572A (is) Orkuríkar sýklódextrínfléttur
DK1075281T3 (da) Polyol-IFN-beta-konjugater
DE69932980D1 (de) Resolversignalverarbeitungssystem
NO20010193L (no) Tiobenzimidazol-derivater
ATE236136T1 (de) Benzosulfonderivate
NO994875D0 (no) Forbundne metallkomplekser
ATE259810T1 (de) Phenyl-xanthinderivate
NO20010514L (no) Aminometylkarboksylsyre-derivater
DE59907315D1 (de) Fahrzeugrechneranordnung
ATE234316T1 (de) Metallocenkomplexe
DE69902762D1 (de) Riser-spannanordnung
DE69925655D1 (de) Rückleuchte
DK1115716T3 (da) 2-phenylpyran-4-on-derivater
ATE233253T1 (de) Chromanderivate
DK1134219T3 (da) Cucloalkylsubstituerede aminomethylpyrrolidinderivater
DK1060183T3 (da) 5-deoxycytidinderivater
FI980759A0 (fi) Taetningskonstruktion foer suglaodan i en sugvals
DE59907635D1 (de) Pyrazolyldioxothiochromanoyl-derivate
SE9901098L (sv) Fördelarlåda
FI980743A0 (fi) Gap-valsformare i en pappersmaskin
DE59807199D1 (de) Zerspaner
FIU980508U0 (fi) Puukuitulevy
UA2866S (uk) Втулка
FI4121U1 (fi) Poikittaiskuljetin
DK199800333U3 (da) Kombinationsprodukt